首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1463278

全球血浆分馏市场规模、份额、成长分析、按产品、按方法、按应用、按最终用途 - 产业预测 2024-2031

Global Plasma Fractionation Market Size, Share, Growth Analysis, By Product, By Method, By Application, By End Use - Industry Forecast 2024-2031

出版日期: 2024年04月09日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球血浆分离市场规模约为308.7亿美元，预计将从2023年的334.3亿美元增至2031年的632.7亿美元，预测期内（2024-2031年）复合年增长率为8.3% 。

在 COVID-19 大流行期间，恢復期血浆的需求增加，因为医生将其用作病毒感染患者的初始治疗方法。例如，根据 Frontiers 2021 年 6 月的一篇论文，恢復期血浆在全球广泛用于治疗住院的 COVID-19 患者并减缓疾病进展。研究表明，恢復期血浆输注与症状改善和病毒清除有关，导致治疗 COVID-19 患者的血浆成分需求最初激增。然而，随着疫情的减弱和感染该病毒的人数减少，所分析的市场预计将在研究预测期内实现稳定成长。有几个具体因素正在推动市场的扩张。其中包括免疫球蛋白在各个治疗领域的使用不断增加、老年人口的不断扩大、罕见疾病发病率的上升以及全球血浆采集设施的激增。例如，根据世界卫生组织 2022 年 10 月的统计数据，到 2050 年，全球 60 岁以上人口的比例预计将增加近两倍，其中很大一部分老年人口居住在低收入和中等收入国家。此外，主要市场参与者采取的各种倡议，包括产品发布、合作、併购和收购，旨在将先进的血浆分离方法和产品引入市场，预计将为市场扩张做出积极贡献。例如，2022 年 1 月，Octapharma 获得授权扩大 Cutaquig 在欧盟 (EU) 的使用。 Cutaquig 是一种皮下注射的人类免疫球蛋白，为许多患有遗传性免疫缺陷的患者提供灵活的治疗选择。总体而言，预计老年人口的增加，加上罕见疾病盛行率的增加、血浆采集中心的激增以及主要市场参与者的各种倡议，预计将对预测期内的市场成长产生积极影响。然而，该行业面临限制，例如血浆蛋白产品加工的严格法规、高定价和报销挑战。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2021 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率（%），2021年

主要公司简介

CSL Behring
Grifols
Octapharma
Baxalta/Shire
Kedrion
China Biologic Products Holdings
Sanquin
Bio Products Laboratory
Japan Blood Products Organization
LFB Group
Shanghai RAAS Blood Products
Green Cross Corporation
Baxter International Inc.
Takeda Pharmaceutical Company Limited
Beijing Tiantan Biological Products
Biotest AG
China National Pharmaceutical Group Co. (Sinopharm)
GC Pharma
ADMA Biologics
Emergent BioSolutions

简介目录

Product Code: SQMIG35H2165

Global plasma fractionation market size was valued at around 30.87 billion in 2022 and is expected to rise from USD 33.43 billion in 2023 to reach a value of USD 63.27 billion by 2031, at a CAGR of 8.3 % over the forecast period (2024-2031).

Convalescent plasma witnessed heightened demand during the COVID-19 pandemic as doctors utilized it as an initial treatment for virus-infected patients. For example, according to a June 2021 Frontiers paper, convalescent plasma was extensively employed worldwide to treat hospitalized COVID-19 patients and mitigate disease progression. Studies have indicated that convalescent plasma transfusion is associated with improved symptomatology and virus clearance, leading to an initial surge in the need for plasma fractions to treat COVID-19 patients. However, as the pandemic waned and fewer individuals contracted the virus, the analyzed market is expected to witness steady growth over the study's forecast period. Several specific factors are fueling the expansion of the market. These include the increasing utilization of immunoglobulins across various therapeutic domains, the expanding elderly population, coupled with the rising incidence of rare diseases, and the proliferation of plasma collection facilities globally. For instance, according to WHO statistics from October 2022, the proportion of individuals worldwide aged over 60 is projected to nearly triple by 2050, with a significant portion of the elderly population residing in low- and middle-income countries. Furthermore, various initiatives undertaken by major market players, including product launches, partnerships, mergers, and acquisitions, aimed at introducing advanced plasma fractionation methods and products to the market, are expected to contribute positively to market expansion. For instance, in January 2022, Octapharma received authorization to expand the use of Cutaquig in the European Union (EU). Cutaquig, a subcutaneously administered human immunoglobulin, offers flexible therapeutic options for numerous patients with inherited immune deficiencies. Overall, the projected rise in the elderly population, coupled with an increase in the prevalence of rare diseases, the proliferation of plasma collection centers, and various initiatives by major market players, are all anticipated to positively impact market growth during the forecast period. However, the industry faces constraints such as stringent regulations governing the processing of plasma protein products, high pricing, and reimbursement challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the global plasma fractionation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Plasma Fractionation Market Segmental Analysis

The global plasma fractionation market is segmented based on product, method, application, end use, and region. By product, the market is segmented into albumin, immunoglobulins, coagulation factors, protease inhibitors. By method, the market is segmented into centrifugation, depth filtration, and chromatography. By application, the market is segmented into neurology, hematology, oncology, immunology, and pulmonology. By end use, the market is segmented into hospitals & clinics, clinical research, and others. By region, the market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Plasma Fractionation Market

The aging population significantly drives the plasma fractionation market. As individuals age, they become more susceptible to chronic illnesses and necessitate medical interventions, which often include plasma-derived products. This growing demographic of elderly individuals contributes to the increasing demand for plasma fractionation products as healthcare providers seek to address the healthcare needs associated with aging populations.

Restraints in the Global Plasma Fractionation Market

The high cost of plasma fractionation products poses a significant restraint on market growth. Manufacturing these products involves substantial expenses, rendering them unaffordable for certain patients and healthcare systems. This cost barrier limits access to these crucial treatments and hampers the overall growth potential of the market.

Market Trends of the Global Plasma Fractionation Market

Immunoglobulins serve as the primary treatment for various immunologic, hematologic, and neurologic conditions. Technological advancements in the past decade have led to increased diagnoses of immunological disorders. Consequently, there is a growing clinical demand for immunoglobulins, driven by the expanding genetic research aimed at defining and diagnosing immunodeficiency disorders. According to IG Living, a publication for the immune globulin (IG) community, immunoglobulins are utilized for numerous on- and off-label indications, with off-label uses comprising a significant portion, ranging from 20% to 60%, of their clinical application. Notably, the use of immunoglobulins for off-label purposes has surpassed their on-label applications in recent years. Furthermore, the prevalence of rare and autoimmune diseases, coupled with increased global research in immunology, is propelling the market's growth. According to the National Center for Advancing Translational Sciences, only a fraction of the 7,000 to 10,000 rare diseases identified have any form of treatment, indicating a vast unmet medical need. The surge in the incidence of rare disorders is contributing to the expansion of the immunoglobulin market, as these conditions necessitate ongoing treatment and management with immunoglobulin therapy.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Plasma Fractionation Market by Product

Market Overview
Albumin
Immunoglobulins
Coagulation Factors
and Protease Inhibitors

Global Plasma Fractionation Market by Method

Market Overview
Centrifugation
Depth Filtration
and Chromatography

Global Plasma Fractionation Market by Application

Market Overview
Neurology
Hematology
Oncology
Immunology
and Pulmonology

Global Plasma Fractionation Market by End Use

Market Overview
Hospitals & Clinics
Clinical Research and Others

Global Plasma Fractionation Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

CSL Behring
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxalta/Shire
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kedrion
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
China Biologic Products Holdings
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanquin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio Products Laboratory
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Japan Blood Products Organization
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LFB Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai RAAS Blood Products
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Green Cross Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beijing Tiantan Biological Products
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biotest AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
China National Pharmaceutical Group Co. (Sinopharm)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GC Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ADMA Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments